Cardio3 BioSciences to open manufacturing site in Rochester, MN, US

Published: 23-Mar-2015
Research & Development Cardiovascular Pharmaceutical

To support CHART-2 Phase III trial and growth in the US


Cardio3 BioSciences (C3BS), a Belgian clinical stage biotechnology company, plans to open a new US-based manufacturing facility in Rochester, Minnesota.

The 1,000m2 facility will be located in the Minnesota Bio Business Centre and will initially be used to manufacture a cardiovascular product candidate C-Cure for use in CHART-2, a Phase III clinical trial, and its recently acquired CAR T-cell therapies portfolio. It will also serve as a base for the company’s research and clinical collaboration with Mayo Clinic, which is also located in Rochester.

C-Cure is an autologous cellular therapy for the treatment of congestive heart failure that is based on C3BS's Cardiopoiesis platform, initially developed using fundamental research and technology from the Mayo Clinic.

C3BS will receive non-dilutive funding from the Minnesota Department of Employment and Economic Development (DEED) and the Minnesota Job Creation Fund once it completes its investment and staffing goals.

  • Companies:
  • Cardio3 Biosciences
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Read more
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  4. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Research & Development

Cardio3 BioSciences establishes US subsidiary

Belgian biotechnology firm adds Rochester, MN operation
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now